International liver transplantation society consensus statement on hepatitis c management in liver transplant recipients

Transplantation

Volumn 101, Issue 5, 2017, Pages 956-967

  Terrault, Norah A ^a   Berenguer, Marina ^b   Strasser, Simone I ^c   Gadano, Adrian ^d   Lilly, Les ^e   Samuel, Didier ^f   Kwo, Paul Y ^g   Agarwal, Kosh ^h   Curry, Michael P ⁱ   Fagiuoli, Stefano ^j   Fung, James Y Y ^k   Gane, Edward ^l   Brown, Kimberly A ^m   Burra, Patrizia ⁿ   Charlton, Michael ^o   Pessoa, Mario G ^p   McCaughan, Geoff W ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f HÔPITAL PAUL BROUSSE   (France)

^g STANFORD UNIVERSITY   (United States)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k QUEEN MARY HOSPITAL   (Hong Kong)

^l AUCKLAND CITY HOSPITAL   (New Zealand)

^m HENRY FORD HOSPITAL   (United States)

ⁿ UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^o Utah Intermountain Transplant and Regenerative Medicine Center   (United States)

^p UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VELPATASVIR;

ANTIVIRAL THERAPY; CHOLESTATIC HEPATITIS; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; GRAFT RECIPIENT; HEALTH CARE PERSONNEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MEDICAL SOCIETY; MIXED INFECTION; NONHUMAN; RECURRENT DISEASE; REVIEW; TREATMENT DURATION; CHOLESTASIS; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; END STAGE LIVER DISEASE; GRAFT REJECTION; LIVER CIRRHOSIS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PROCEDURES; VIROLOGY;

ANTIVIRAL AGENTS; CHOLESTASIS; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; GRAFT REJECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RECURRENCE;

EID: 85014070839     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001704     Document Type: Review

References (70)

1. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
2. Terrault N, McCaughan G, Curry M, et al. International Liver Transplantation Society Consensus Statement on hepatitis C management in liver transplant candidates. Transplantation. 2017;101:945-955.
3. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32:673-684.
4. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896.
5. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12:1192-1204.
6. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reducesmortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46:459-465.
7. Dhanasekaran R, Sanchez W, Mounajjed T, et al. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015;35:2433-2441.
8. Kwok RM, Ahn J, Schiano TD, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl. 2016;22:1536-1543.
9. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;48:108-116.
10. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.
11. Poordad F, Schiff E, Vierling J, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493-1505.
12. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl JMed. 2014;371:2375-2382.
13. Agarwal K, Brown JR, Dumas E, et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir dasabuvir and ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3-6). EASL. 2017.
14. Nguyen NH, Yee BE, Chang C, et al. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterol. 2016;3:e000066.
15. Brown RS Jr, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22:24-33.
16. Jackson WE, Hanouneh M, Apfel T, et al. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience. Clin Transplant. 2016;30: 709-713.
17. Reddy K, Sulkowski M, Hassan M, et al. Safety and Efficacy of New DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: interval results from the HCV-TARGET Study.JHepatol. 2016;64:S783-S784
18. Coilly A, Fougerou-Leurent C, de Ledinghen V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence-the ANRS CUPILT study. J Hepatol. 2016;65:711-718.
19. Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017; 166:109-117.
20. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005;5:118-124.
21. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011; 17:528-538.
22. Wiesner R, Sorrell M, Villamil F, et al. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1-S9.
23. Consensus conference: Indications for Liver Transplantation, January 19 and 20, 2005, Lyon-Palais Des Congres: text of recommendations (long version). Liver Transpl. 2006;12:998-1011.
24. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746-1756.
25. BerenguerM, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679-687.
26. Bizollon T, Ahmed S, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003;52:283-287.
27. CharltonM, Gane E,Manns M, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108-117.
28. Levitsky J, Verna E, O'Leary J, et al. Perioperative ledipasvir-sofosbuvir for HV in liver-transplant recipients. New Engl J Med. 2016;375:2106-2108.
29. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32:852-858.
30. Saab S, Niho H, Comulada S, et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int. 2005;25:940-945.
31. McCashland T, Watt K, Lyden E, et al. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007;13: 1246-1253.
32. Dumortier J, Leroy V, Duvoux C, et al. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Liver Transpl. 2016;22:1367-1378.
33. Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64: 234-238.
34. Rosen HR, Prieto M, Casanovas-Taltavull T, et al. Validation and refinement of survival models for liver retransplantation. Hepatology. 2003;38: 460-469.
35. Gane E, Manns M, McCaughan G, et al. Ledipasvir/Sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: SOLAR-1 and-2 trials. Hepatol Int. 2016;10:S1.
36. Biggins SW, Gralla J, Dodge JL, et al. Survival benefit of repeat liver transplantation in the United States: a serialMELD analysis by hepatitisC status and donor risk index. Am J Transplant. 2014;14:2588-2594.
37. Song AT, Sobesky R, Vinaixa C, et al. Predictive factors for survival and score application in liver retransplantation for hepatitisC recurrence.World J Gastroenterol. 2016;22:4547-4558.
38. Taga S, Washington M, Terrault N, et al. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg. 1998;4:304-310.
39. Verna EC, Abdelmessih R, Salomao MA, et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19:78-88.
40. Satapathy SK, Sclair S, Fiel MI, et al. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C postliver transplantation. Hepatol Res. 2011;41:328-339.
41. Antonini TM, Sebagh M, Roque-Afonso AM, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant. 2011;11:1686-1695.
42. Ong JP, Younossi ZM, Gramlich T, et al. Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation. 2001;71: 1486-1487.
43. Fukuhara T, Morita K, Takeishi K, et al. Early diagnosis and treatment resolved cholestatic hepatitis C without fibrosis after living donor liver transplantation: report of a case. Surg Today. 2010;40:982-985.
44. Fontana RJ, Hughes EA, Appelman H, et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl. 2012;18: 1053-1059.
45. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823-830.
46. Herzer K, Welzel TM, Ferenci P, et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: interim results of a multicenter compassionate use program. Hepatology. 2015;62:341a-341a.
47. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015;62:25-30.
48. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61:1880-1886.
49. Saab S, Jimenez M, Bau S, et al. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis. Clin Transplant. 2015; 29:813-819.
50. Issa D, Eghtesad B, Zein NN, et al. Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation. Int J Organ Transplant Med. 2016;7:38-45.
51. Kim B, Trivedi A, Thung SN, et al. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis. 2014;34:108-112.
52. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923-927.
53. Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol. 2015;13:1993-2001. e1-2.
54. Salcedo-PlazaM, Vinaixa C,Castells L, et al. Efficacy and clinical impact of Daclatasvir-based antiviral therapy in severe recurrent hepatitis C after liver transplantation. Results from a Multicenter Spanish Group. Cohort SETH (Spanish Liver Transplantation Society). J Hepatol. 2016;64:S547.
55. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485-1494.
56. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716-726.
57. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12:1866-1876.
58. Terrault N, Barin B, Schiano T, et al. Safety and efficacy of antiviral therapy in hepatitis C virus (HCV)-human immunodeficiency virus (HIV) coinfected liver transplant (LT) recipients. Am J Transplant. 2012;12:85-85.
59. Tateo M, Roque-Afonso AM, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. Aids. 2009;23:1069-1076.
60. Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10:1268-1275.
61. Londono M, Manzardo C, Rimola A, et al. IFN-free therapy for HIV/HCVcoinfected patients within the liver transplant setting. J Antimicrob Chemother. 2016;71:3195-3201.
62. Campos-Varela I, Straley S, Agudelo EZ, et al. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl. 2015;21:272-274.
63. Grant JL, Hawkins C, Brooks H, et al. Successful sofosbuvir-based therapy in HIV/hepatitisC virus coinfected liver transplant recipientswith recurrent hepatitis C virus infection. Aids. 2016;30:93-98.
64. Antonini T, Coilly A, Radenne S, et al. P0804: efficacy of sofosbuvir-based treatment regimens inHIV/HCV co-infected patients after liver transplantation: the ANRS CO23 CUPILT study. J Hepatol. 2015;62:S635-S636.
65. Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, et al. Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 2016;55:197-208.
66. Badri PS, Parikh A, Coakley EP, et al. Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection. Ther Drug Monit. 2016;38:640-645.
67. Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20:235-241.
68. Raschzok N, Schott E, Reutzel-Selke A, et al. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C. Transpl Infect Dis. 2016;18:896-903.
69. Saab S, Rheem J, Jimenez M, et al. Curing hepatitis C in liver transplant recipients is associated with changes in immunosuppressant use. J Clin Transl Hepatol. 2016;4:32-38.
70. Kiser JJ. Clinically significant drug-drug interactions between hepatitis C virus and HIV treatments. Top Antivir Med. 2016;24:106-110.